At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihistamines; Nootropics; Small molecules
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders
Most Recent Events
- 25 Aug 1998 No-Development-Reported for Cognition disorders in United Kingdom (Unknown route)
- 20 Sep 1996 Preclinical development for Cognition disorders in United Kingdom (Unknown route)